EIB Lends Théa €150 Million for European R&D

The European Investment Bank has granted the ophthalmic drugmaker a second loan to fund research and industrial investment across Europe.

Updated on Nov. 19, 2026 in Healthcare

Photograph-style view of a row of stainless-steel bioreactor vessels and a frosted glass microfluidic tray in a clean, pale research hall.
The European Investment Bank granted drugmaker Théa a €150 million loan to fund eye-care research and industrial investment across Europe. AI Illustration. Upload story photo >

The European Investment Bank provided €150 million in financing to Théa to support its research and development investments in Europe. The loan is the second the EIB has granted the company, following a €50 million loan signed in 2021.

Why it matters

The financing backs development of new molecules, formulations and drug delivery systems for eye care, supporting Europe's pharmaceutical innovation base. It also draws on the European Commission's InvestEU programme, which uses public guarantees to mobilise private investment.

The €150 million loan is three times the size of the initial €50 million EIB loan signed in 2021, with Théa reinvesting over 12 per cent of its €1,020 million 2025 turnover into research each year. The source does not detail how the funds will be allocated across Théa's European sites.

The players

European Investment Bank

The European Investment Bank is the European Union's public lending institution, which finances projects that advance EU policy objectives.

Théa

Théa is a French ophthalmic pharmaceutical company founded in 1994 and headquartered in Clermont-Ferrand, operating in more than 75 countries.

The details

The financing agreement supports Théa's research and development investments in Europe, including development of new molecules, new formulations and innovative drug delivery systems for ophthalmic use. The project received backing from the European Commission's InvestEU programme, which is expected to benefit from its guarantee.

Timeline

  1. 2021: EIB signed the initial €50 million loan to Théa.

  2. 19 November 2026: EIB announced the €150 million financing.

Industry Dynamics

The €150 million loan is backed by the InvestEU programme, whose guarantee structure is expected to mobilise at least €427 billion in additional investment across the EU. The deal reflects a broader pattern of public development banks co-financing private pharmaceutical R&D in Europe.

The funding is directed at new eye-care formulations and drug delivery systems, which could expand treatment options for ophthalmic conditions over time. The source does not indicate when any resulting products would reach patients.

The takeaway

Public development finance can de-risk long-term pharmaceutical research, and companies that reinvest a large share of revenue into R&D are well positioned to attract such support. Readers following eye-care innovation should watch for product announcements tied to these programmes.

Further reading

For more on public financing of medical research, see the Healthcare section.

Source note: This article includes information reported by EIB.